CIC-NUTM1 Sarcomas Affecting the Spine.


Journal

Archives of pathology & laboratory medicine
ISSN: 1543-2165
Titre abrégé: Arch Pathol Lab Med
Pays: United States
ID NLM: 7607091

Informations de publication

Date de publication:
01 06 2022
Historique:
accepted: 11 05 2021
pubmed: 16 9 2021
medline: 1 6 2022
entrez: 15 9 2021
Statut: ppublish

Résumé

Tumors harboring CIC-NUTM1 fusion are a newly recognized rare sarcoma, but the documented cases are still limited. It is unclear whether it is the same as classic CIC-DUX4 sarcoma in terms of its clinical, pathologic, and behavioral aspects. To further explore the clinicopathologic characteristics of CIC-NUTM1 sarcoma. The cases were diagnosed based on immunophenotype, next-generation sequencing, and fluorescence in situ hybridization tests and compared with the reported CIC-NUTM1 sarcomas in the literature. Three cases of CIC-NUTM1 sarcomas involving the spine in adults were described. The tumors occurred in 2 men and 1 woman, aged 38 to 61 years. Two tumors were located in thoracic vertebrae and 1 in a cervical vertebra. All were locally advanced lesions destroying the bone and soft tissues without spinal cord involvement or metastasis. The tumors were composed of monomorphic small to medium-sized cells with round to epithelioid appearance. The architecture was lobulated and solid with diffuse or multifocal myxoid stroma. Next-generation sequencing revealed an in-frame fusion between CIC (exon 16 or 17) and NUTM1 (exon 5 or 6) in 3 cases. Fluorescence in situ hybridization confirmed CIC and NUTM1 breaks, and immunohistochemistry showed NUT staining in the nucleus. The patients died of disease 8 to 15 months (mean, 10.7 months) after presentation. Of the CIC-NUTM1 sarcomas reported in the literature along with our cases (n = 11), 8 cases developed in axial bone (5 spine, 3 skull base). CIC-NUTM1 sarcomas demonstrate distinct anatomic tropism for the axial skeleton and unfavorable behavior compared with classic CIC sarcoma.

Identifiants

pubmed: 34525172
pii: 470374
doi: 10.5858/arpa.2021-0153-OA
doi:

Substances chimiques

Biomarkers, Tumor 0
CIC protein, human 0
Nuclear Proteins 0
Oncogene Proteins, Fusion 0
Repressor Proteins 0
Transcription Factors 0

Types de publication

Case Reports Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

735-741

Auteurs

Shaomin Yang (S)

From the Department of Pathology, School of Basic Medical Sciences, Third Hospital, Peking University Health Science Center, Beijing, China (Yang, Zhang).

LiLi Liu (L)

From the Department of Pathology, Peking University People's Hospital, Beijing, China (Liu, Yan, Shen).

Yu Yan (Y)

From the Department of Pathology, Peking University People's Hospital, Beijing, China (Liu, Yan, Shen).

Liang Jiang (L)

From the Department of Orthopedics (Jiang), Peking University Third Hospital, Beijing, China.

Songbo Han (S)

From the Department of Radiology (Han), Peking University Third Hospital, Beijing, China.

Danhua Shen (D)

From the Department of Pathology, Peking University People's Hospital, Beijing, China (Liu, Yan, Shen).

Bo Zhang (B)

From the Department of Pathology, School of Basic Medical Sciences, Third Hospital, Peking University Health Science Center, Beijing, China (Yang, Zhang).

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH